Foresite Capital is a leading venture capital and growth equity firm focused on healthcare and life sciences. The firm invests in startups at all stages, from seed to late-stage rounds, with a particular emphasis on Series A to C investments. Foresite Capital has raised multiple funds, including a recent $900 million fund, to support innovative companies in biotech, genomics, and digital health.
The firm's portfolio includes notable companies such as 10x Genomics, 23andMe, Insitro, and Relay Therapeutics. Foresite Capital offers strategic guidance and operational support to its portfolio companies, leveraging its team's deep expertise in healthcare and life sciences. The firm is known for making significant investments in cutting-edge technologies, including AI-driven drug discovery and development platforms.
Foresite Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Total Investments97
Current Portfolio Count56
Total Portfolio Exits6
Top Investment Stages
Series B34 (40.5%)
Series C22 (26.2%)
Series A16 (19.0%)
Series D7 (8.3%)
Post Ipo Equity5 (6.0%)
Stage Mix
Series B 40%Series C 26%Series A 19%Series D 8%Post Ipo Equity 6%
Concentration shown as share of disclosed investments by stage.
Foresite Capital - Classification
- Also Known As
- Foresite Capital Management, LLC
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- 523940Portfolio Management and Investment Advice
- SIC
- 6000Depository Institutions
- 6720Investment Offices
- 6722Management Investment Offices, Open-end